Popular Articles
Natural Remedies

New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate And Treatment Failure In Patients With Chronic ITP
Amgen Inc. (Nasdaq: AMGN) today released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterised by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events. The study results show Nplate significantly reduced the incidences of splenectomy and treatment failures in non-splenectomised adult patients with chronic ITP when compared to medical SOC. The results were presented today as an oral presentation at the 14th congress of the European Hematology Association (EHA abstract #1672).
generic viagra online
Latest Arizona State University-Southwest Poll Reveals A Focus On Health-Care Issues
A majority of Southwesterners - 86 percent - think the U.S. health care system is in need of some reform, and more than half - 53 percent - indicate "a great deal of reform" is needed, according to the most recent Arizona State University-Southwest Poll.
News of the day
HearAtLast To Launch Exclusive Groundbreaking Neuro-CompensatorTM Technology Hearing Aids From VitaSound
HearAtLast Holdings, Inc. (PINKSHEETS: HRAL), a leading provider of suitable affordable solutions to clients with hearing needs in the billion dollar hearing loss market, announced that in keeping with its tradition of bringing innovative new products to consumers, the Company announces the unveiling of breakthrough hearing products based on the Neuro-Compensator™ algorithm technology from VitaSound Audio.
Cardiovascular

World Health Assembly Forced To Postpone Decision On Viral Hepatitis

On the second annual World Hepatitis Day, the World Hepatitis Alliance today called on governments not to forget the plight of 500 million people living with hepatitis B and C, as the World Health Assembly postpones discussion of a World Health Organization (WHO) resolution on viral hepatitis - one of the biggest threats to global health. The 62nd World Health Assembly, starting in Geneva on 18 May, has been shortened in response to the global efforts required to tackle H1N1 influenza. As a result a scheduled resolution on viral hepatitis, submitted by Brazil and entitled "Proposal for the Establishment of a World Day for the Struggle against Viral Hepatitis and other issues relating to the Disease", which calls for action to improve hepatitis awareness, diagnosis, prevention, treatment and support will now not be discussed until 2010 at the earliest. Charles Gore, President of the World Hepatitis Alliance explained that the hepatitis community recognised the need for a concerted effort to tackle H1N1 influenza, but stressed that global health leaders can no longer afford to ignore hepatitis B and C. "Viral hepatitis has never been properly addressed at a global level and the consequences have been disastrous" commented Mr Gore. "Despite this disappointing postponement, we look forward to working with both the WHO Executive Board and governments around the world to ensure that a resolution is passed in 2010 and that a comprehensive, coordinated approach is adopted before another million people die." Chronic viral hepatitis B and C affects one in 12 people globally and approximately one person dies every 30 seconds, meaning that one million people will die before the World Health Assembly next meets in 2010. Since the hepatitis B and C viruses were first discovered in 1967 and 1988 respectively, there has not been a single WHO resolution that fully addresses the challenges of the global epidemic. 19 May marks the second World Hepatitis Day, and over 200 patient groups from more than 50 countries have been recognising the day by asking the question "Am I Number 12?" - an awareness raising campaign aimed at highlighting the shocking statistic that one in 12 people worldwide are living with either chronic hepatitis B or chronic hepatitis C. While this is far higher than the prevalence of HIV or any cancer, awareness is inexplicably low and the majority of those infected are unaware. Did You Know? - Approximately 500 million people worldwide are currently infected with hepatitis B or C1 - This is over 10 times the number infected with HIV/AIDS2 - Between them, hepatitis B and C kill one million people a year1 - One in every three people on the planet has been exposed to either or both viruses - Most of the 500 million infected do not know Messages of Support for the World Hepatitis Alliance The following people have provided quotes expressing their support to the World Hepatitis Alliance campaign for a WHO resolution on viral hepatitis. For further information please contact worldhepday@fleishman.com - Dr. Michael Houghton, co-discoverer of the hepatitis C virus - Prof. Baruch Blumberg, Nobel Laureate, co-discoverer of the hepatitis B virus and co-inventor of the hepatitis B vaccine - Prof. Muhammad Yunus, Nobel Laureate and global Economist World Hepatitis Alliance


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):